AM-Pharma is backed by a strong syndicate of international investors, including Venture Capital Funds and Corporate Venture Funds. To date, the company has raised over €65 million equity.

The Series D funding round was completed in 2011 and totalled €29.2M. An additional €12.2M was raised in 2014.

In addition, the Dutch Ministry of Economic Affairs (Netherlands Enterprise Agency - RVO) granted AM-Pharma non-dilutive financing in the form of two loans of up to possibly €10M combined.

The Company’s main investors include:


Gilde Healthcare


Latest News

October 24 2018
JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury
Read more.

March 9 2018
AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
Read more.